NXY-059


Also found in: Wikipedia.

NXY-059

A free radical-trapping agent that has been found to be neuroprotective in stoke in animals. It has been tested in ischaemic stroke in humans and was found to reduce disability at 90 days but did not improve putcome in other respects.
References in periodicals archive ?
The recently published Cerebral Hemorrhagic and NXY-059 Treatment Trial found no relationship between prior antiplatelet use and the volume of ICH on baseline CT, ICH growth, or clinical outcome at 90 days.
NXY-059 (disufenton sodium) is a free radical-trapping agent that significantly reduced disability and hemorrhagic transformation in acute ischemic stroke patients in the SAINT-I clinical trial [134].
The trial found no significant benefit to stroke patients from an antioxidant called NXY-059, which was intended to inhibit damage by free radicals.
The news comes at a difficult time for AstraZeneca, which was relying on established medicines such as Nexium to drive sales following the failure of clinical trials for new drugs, such as stroke drug NXY-059.
The UK's second-largest drugmaker ended development of the NXY-059 treatment after patients showed no improvement during the tests.
The UK's second-largest drug makers ended development of the NXY-059 treatment after patients showed no improvement during clinical trials.
A trial involving more than 1,700 patients in 154 hospitals around the world found that the treatment, currently known as NXY-059, has produced "promising" results.
Researchers say a trial involving more than 1,700 patients in 154 hospitals around the world found the treatment, known as NXY-059, has produced promising results.
Safety and tolerability of NXY-059 at higher target concentrations in acute stroke patients.
com/reports/c42590) has announced the addition of Financial Markets Research: Renovis, Inc's NXY-059 - Safety Profile and Unmet Need Could Drive Approval to their offering.
Since that time, Renovis has had its ups and downs, but the data so far on NXY-059 looks very encouraging.
Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window.